HC Wainwright Issues Positive Estimate for MIRM Earnings

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for Mirum Pharmaceuticals from ($0.15) to ($0.12), maintaining a "Buy" rating with an $80 price target.
• Mirum Pharmaceuticals reported a revenue increase of 64.1% year-over-year for the latest quarter, with actual earnings of ($0.12) per share, outperforming the expected ($0.31).
• Insider selling was noted, including CEO Christopher Peetz selling 40,000 shares valued at approximately $2.21 million, reflecting a 22.39% decrease in his ownership stake.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Investment analysts at HC Wainwright upped their Q3 2025 EPS estimates for Mirum Pharmaceuticals in a research report issued to clients and investors on Thursday, August 7th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.12) per share for the quarter, up from their previous forecast of ($0.15). HC Wainwright currently has a "Buy" rating and a $80.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals' Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at $0.02 EPS, FY2027 earnings at $0.88 EPS, FY2028 earnings at $1.35 EPS and FY2029 earnings at $2.63 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.19. Mirum Pharmaceuticals had a negative net margin of 13.65% and a negative return on equity of 24.76%. The company had revenue of $127.79 million during the quarter, compared to analyst estimates of $107.91 million. During the same quarter in the prior year, the business earned ($0.52) earnings per share. The business's quarterly revenue was up 64.1% compared to the same quarter last year.

Several other brokerages also recently weighed in on MIRM. Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Raymond James Financial reiterated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research note on Thursday, August 7th. JMP Securities set a $81.00 target price on shares of Mirum Pharmaceuticals and gave the company a "market outperform" rating in a research note on Thursday, August 7th. Stifel Nicolaus set a $89.00 target price on shares of Mirum Pharmaceuticals and gave the stock a "buy" rating in a research report on Monday. Finally, Evercore ISI upped their target price on shares of Mirum Pharmaceuticals from $77.00 to $89.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Mirum Pharmaceuticals has a consensus rating of "Buy" and an average target price of $74.13.

Mirum Pharmaceuticals Stock Down 0.7%

NASDAQ MIRM traded down $0.45 during trading hours on Monday, reaching $64.69. 201,099 shares of the company traded hands, compared to its average volume of 492,698. The company has a 50 day moving average of $52.06 and a two-hundred day moving average of $47.55. The company has a current ratio of 3.13, a quick ratio of 2.97 and a debt-to-equity ratio of 1.21. Mirum Pharmaceuticals has a 12 month low of $36.86 and a 12 month high of $67.45. The stock has a market capitalization of $3.25 billion, a PE ratio of -53.27 and a beta of 0.94.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 10,000 shares of the company's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $58.00, for a total value of $580,000.00. Following the completion of the transaction, the senior vice president owned 2,426 shares in the company, valued at $140,708. This represents a 80.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Christopher Peetz sold 40,000 shares of the stock in a transaction on Monday, August 11th. The stock was sold at an average price of $62.00, for a total value of $2,480,000.00. Following the transaction, the chief executive officer owned 138,641 shares of the company's stock, valued at $8,595,742. The trade was a 22.39% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 91,041 shares of company stock valued at $5,320,624 over the last three months. 14.36% of the stock is currently owned by insiders.

Institutional Trading of Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC boosted its position in shares of Mirum Pharmaceuticals by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 943,344 shares of the company's stock valued at $39,016,000 after purchasing an additional 7,147 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Mirum Pharmaceuticals by 8.1% during the fourth quarter. Russell Investments Group Ltd. now owns 25,960 shares of the company's stock valued at $1,073,000 after purchasing an additional 1,945 shares in the last quarter. Invesco Ltd. increased its position in Mirum Pharmaceuticals by 5.2% during the fourth quarter. Invesco Ltd. now owns 299,279 shares of the company's stock valued at $12,375,000 after acquiring an additional 14,747 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Mirum Pharmaceuticals by 3.5% in the fourth quarter. Legal & General Group Plc now owns 40,820 shares of the company's stock worth $1,688,000 after buying an additional 1,389 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of Mirum Pharmaceuticals by 67.5% in the fourth quarter. Renaissance Technologies LLC now owns 101,248 shares of the company's stock worth $4,187,000 after buying an additional 40,800 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.